You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

CLINICAL TRIALS PROFILE FOR TAMOXIFEN CITRATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Tamoxifen Citrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002460 ↗ Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer Unknown status Cancer Research UK Phase 3 1987-09-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. PURPOSE: Phase III trial to compare the effectiveness of adjuvant therapy using tamoxifen or ovarian ablation with goserelin or both in treating women with stage I or stage II breast cancer.
NCT00002528 ↗ Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer Completed International Breast Cancer Study Group Phase 3 1993-05-01 RATIONALE: Removing axillary lymph nodes may be effective in stopping the spread of breast cancer cells. It is not yet known if surgery to remove breast cancer is more effective with or without lymph node removal. PURPOSE: Randomized phase III trial to compare the effectiveness of breast surgery with or without removal of axillary lymph nodes in treating women who have stage I or stage IIA breast cancer.
NCT00002529 ↗ Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer Completed International Breast Cancer Study Group Phase 3 1993-05-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the uptake of estrogen. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which treatment regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy during or after combination chemotherapy or hormone therapy alone in treating perimenopausal or postmenopausal women who have stage II or stage IIIA breast cancer.
NCT00002542 ↗ Tamoxifen in Treating Women With High-Risk Breast Cancer Completed NCIC Clinical Trials Group Phase 3 1993-07-20 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to study the effectiveness of tamoxifen following surgery and chemotherapy in treating women who have stage I breast cancer at high risk of recurrence or stage II or stage III breast cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tamoxifen Citrate

Condition Name

Condition Name for Tamoxifen Citrate
Intervention Trials
Breast Cancer 79
Stage IIIB Breast Cancer 9
Stage IIIA Breast Cancer 8
Stage IV Breast Cancer 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tamoxifen Citrate
Intervention Trials
Breast Neoplasms 92
Carcinoma 14
Carcinoma in Situ 11
Carcinoma, Intraductal, Noninfiltrating 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tamoxifen Citrate

Trials by Country

Trials by Country for Tamoxifen Citrate
Location Trials
United States 887
Canada 86
United Kingdom 61
Australia 21
China 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tamoxifen Citrate
Location Trials
California 31
Illinois 26
Maryland 24
Minnesota 24
Texas 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tamoxifen Citrate

Clinical Trial Phase

Clinical Trial Phase for Tamoxifen Citrate
Clinical Trial Phase Trials
Phase 4 4
Phase 3 57
Phase 2/Phase 3 1
[disabled in preview] 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tamoxifen Citrate
Clinical Trial Phase Trials
Completed 66
Unknown status 25
Active, not recruiting 17
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tamoxifen Citrate

Sponsor Name

Sponsor Name for Tamoxifen Citrate
Sponsor Trials
National Cancer Institute (NCI) 59
Southwest Oncology Group 11
Cancer and Leukemia Group B 9
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tamoxifen Citrate
Sponsor Trials
Other 215
NIH 59
Industry 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Tamoxifen Citrate: Clinical Trials, Market Analysis, and Projections

Introduction to Tamoxifen Citrate

Tamoxifen citrate is a selective estrogen receptor modulator (SERM) widely used in the treatment of breast cancer, particularly in hormone receptor-positive cases. It works by blocking the estrogen receptors on breast cancer cells, thereby inhibiting the growth of these cells.

Clinical Trials Update

Current and Ongoing Trials

Several clinical trials are ongoing or have recently concluded to evaluate the efficacy and safety of tamoxifen citrate in various settings.

Tamoxifen Citrate or Letrozole With or Without Bevacizumab

A randomized phase III trial at UCSF is investigating the combination of tamoxifen citrate or letrozole with or without bevacizumab in treating women with stage IIIB or stage IV breast cancer. This study aims to determine whether adding bevacizumab, an immunotherapy agent, to hormone therapy enhances treatment outcomes. Patients are randomized into two treatment arms: one receiving endocrine therapy (tamoxifen citrate or letrozole) alone and the other receiving endocrine therapy plus bevacizumab[1].

Hormone Receptor Positive Breast Cancer Study

A double-blind, multicenter, placebo-controlled study at UCSD is comparing the efficacy of letrozole versus placebo in patients with hormone receptor-positive breast cancer. Patients are stratified based on pathologic nodal status, adjuvant tamoxifen citrate therapy, and bone mineral density. The study aims to assess the effectiveness of letrozole in preventing disease progression over a period of up to 5 years[4].

Key Findings and Implications

  • Combination Therapy: The UCSF trial highlights the potential benefits of combining hormone therapy with immunotherapy, which could lead to improved outcomes for advanced breast cancer patients.
  • Long-term Efficacy: The UCSD study focuses on the long-term use of letrozole, which is crucial for understanding its sustained efficacy and safety profile in hormone receptor-positive breast cancer patients.

Market Analysis

Market Size and Growth

The global tamoxifen citrate market is experiencing moderate growth driven by several key factors.

  • Increasing Incidence of Breast Cancer: The rising incidence of breast cancer globally is a significant driver, as it increases the demand for effective treatments like tamoxifen citrate[2][3][5].
  • Awareness and Government Initiatives: Initiatives to raise awareness about breast cancer diagnosis and treatment, especially in developing countries, are boosting market growth. Government initiatives and increased health awareness also contribute to the market expansion[2][3][5].

Market Segmentation

The tamoxifen citrate market is segmented based on type, application, and geography.

  • Type: The market includes experimental grade, food grade, and other types of tamoxifen citrate. However, the primary focus remains on the pharmaceutical grade used in cancer treatment[2].
  • Application: While tamoxifen citrate is predominantly used in breast cancer treatment, it is also categorized under cosmetics and food spices in broader market analyses. The pharmaceutical application remains the most significant segment[2].
  • Geography: The market is divided into North America, Europe, Asia Pacific, and the rest of the world. North America and Europe are currently dominant, but the Asia Pacific region is expected to grow significantly due to increasing health awareness and government initiatives[2][3].

Key Players and Competitive Landscape

The market is competitive with several key players, including Agvar Chemicals Inc., Venus Chemicals, Ar-Ex Laboratories Pvt. Ltd., Cayman Chemical Company, and others. These companies are involved in the production and distribution of tamoxifen citrate and are continuously innovating to improve product efficacy and safety[2][3].

Market Projections

Growth Rate and Revenue

The global tamoxifen citrate market was valued at approximately $208.89 million in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 2.2% from 2023 to 2030, reaching nearly $243.26 million by the end of the forecast period[3].

Drivers and Restraints

  • Drivers: The market is driven by the increasing prevalence of breast cancer, growing awareness campaigns, and the development of effective combination drug therapies. Government initiatives and rising health awareness are also significant drivers[2][3][5].
  • Restraints: The rise in treatment costs and the adverse effects of cancer therapies, such as increased tumor or bone pain, hot flashes, nausea, fatigue, mood swings, depression, headache, and hair thinning, are expected to hamper market growth[2][3].

Consumer and Market Trends

Increasing Demand for Personalized Medicines

There is a growing demand for personalized medicines, chemotherapies, and better diagnostic facilities, which is expected to propel the tamoxifen citrate market. New product launches by pharmaceutical companies, including over-the-counter medications, are also anticipated to contribute to market growth[2][3].

Impact of Digital Health Awareness

Rising consumer health awareness and medical knowledge gained through the internet are driving the sales of over-the-counter medications, including tamoxifen citrate. This trend is expected to continue, influencing market dynamics positively[2][3].

Key Takeaways

  • Clinical Trials: Ongoing trials are exploring the efficacy of tamoxifen citrate in combination with other therapies, which could lead to improved treatment outcomes for breast cancer patients.
  • Market Growth: The global tamoxifen citrate market is growing moderately, driven by the increasing incidence of breast cancer and government initiatives.
  • Segmentation: The market is segmented by type, application, and geography, with pharmaceutical applications being the most significant.
  • Projections: The market is expected to reach nearly $243.26 million by 2030, driven by growing health awareness and demand for personalized medicines.

FAQs

What is the primary use of tamoxifen citrate?

Tamoxifen citrate is primarily used in the treatment of hormone receptor-positive breast cancer by blocking the estrogen receptors on breast cancer cells.

What are the common side effects of tamoxifen citrate?

Common side effects include increased tumor or bone pain, hot flashes, nausea, fatigue, mood swings, depression, headache, and hair thinning[2][3].

How is the global tamoxifen citrate market segmented?

The market is segmented based on type (experimental grade, food grade, etc.), application (pharmaceutical, cosmetics, etc.), and geography (North America, Europe, Asia Pacific, etc.)[2].

What are the key drivers of the tamoxifen citrate market?

Key drivers include the increasing incidence of breast cancer, growing awareness campaigns, government initiatives, and the development of effective combination drug therapies[2][3][5].

What is the projected growth rate of the tamoxifen citrate market?

The market is expected to grow at a CAGR of 2.2% from 2023 to 2030[3].

Which region is expected to dominate the tamoxifen citrate market?

North America is currently dominant, but the Asia Pacific region is expected to grow significantly due to increasing health awareness and government initiatives[2][3].

Sources

  1. UCSF Breast Cancer Trial: Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer[1].
  2. Verified Market Research: Tamoxifen Citrate Market Size And Forecast[2].
  3. Maximize Market Research: Tamoxifen Citrate Market: Industry Analysis and Forecast[3].
  4. UCSD Clinical Trials: Hormone Receptor Positive Breast Cancer Study[4].
  5. EIN Presswire: Global Tamoxifen citrate Market 2019 Analysis, Opportunities and Forecast To 2025[5].
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.